KK3A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
MYQORZO Launch TractionRapid growth in MYQORZO dispenses, prescribers and new-to-brand share indicates meaningful early demand. Continued adoption could establish a recurring commercial revenue base and validate Cytokinetics’ ability to commercialize specialized cardiovascular medicines.
Late-Stage Pipeline ProgressPositive pivotal ACACIA-HCM results and progress across MAPLE-HCM, COMET-HF and AMBER-HFpEF strengthen the pipeline. Multiple late-stage programs create opportunities for additional indications and future revenue beyond the initial product launch.
Improved LiquidityThe larger cash balance provides funding for commercialization, regulatory filings and late-stage trials over the next several quarters. This reduces immediate financing pressure and gives management greater flexibility to execute its pipeline strategy.
Bears Say
Heavy Cash BurnLarge recurring operating outflows mean Cytokinetics is not yet self-funding and must rely on cash reserves, partnerships or capital markets. Sustained investment in launches and trials could consume liquidity quickly if product revenue scales slowly.
Weak Capital StructureNegative equity and substantial debt indicate limited balance-sheet flexibility despite the recent cash raise. This structure can increase dependence on future financing and constrain the company’s ability to absorb clinical, regulatory or commercial setbacks.
Unprofitable And Volatile Revenue BaseRevenue remains sensitive to irregular licensing and milestone payments, while launch and development costs are rising. Persistent losses and higher 2026 expense guidance make durable profitability dependent on sustained MYQORZO growth and future approvals.
Cytokinetics News
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
Currently, no data Available
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is CHF8.86B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 06, 2026. The company reported -CHF1.218 earnings per share for the quarter, beating the consensus estimate of -CHF1.322 by CHF0.104.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.18.
How many shares outstanding does Cytokinetics have?
Currently, no data Available
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -CHF1.218 in its last earnings report, beating expectations of -CHF1.322. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CH:KK3A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF90.03 (― Upside)
CHF90.03 (― Upside)
Blogger Sentiment
Bullish
CH:KK3A Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF9.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
57.02%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
KK3A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.View all CH:KK3A earnings summariesKK3A Stock 12 Month Forecast
Average Price Target
―Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
―